Newer drugs: availability and cost in India

Many newer breast cancer drugs are approved and available in India, including CDK4/6 inhibitors such as ribociclib, palbociclib and abemaciclib, HER2 treatments such as pertuzumab and trastuzumab emtansine, and PARP inhibitors such as olaparib. Some, such as trastuzumab and everolimus, are available as biosimilars or generics at much lower cost. Others, such as some antibody-drug conjugates and oral SERDs, may be recently approved, available only in certain centres, or not yet widely accessible. Costs vary greatly, and the availability of patient support programmes, generics and trials can change what is realistic for each family.

Why availability varies

A drug needs regulatory approval in India, import or local manufacture, and supply to hospitals. Newer drugs may be approved abroad years before reaching Indian pharmacies, and supply can differ between cities.

Why costs vary so much

Patented drugs from a single manufacturer tend to cost more. Once generics or biosimilars arrive, competition often lowers prices considerably. Dosing, duration and support programmes also change the total.

When a drug is not accessible

Your oncologist can suggest alternatives, clinical trials, compassionate access schemes, or treatment sequences that make the best use of what is available.

News about new cancer drugs can create hope and pressure at the same time. It helps to know that newer does not always mean better for every person, and that many established treatments remain highly effective.

Evidence matters more than novelty

A new drug may help a specific group, such as people with a particular mutation, but offer little for others. Your oncologist can explain whether the evidence applies to you.

Beware unverified sources

Drugs bought through unofficial imports or unverified online sellers may be counterfeit or poorly stored. Use authorised channels only.

Cost can affect the plan

If a recommended drug is unaffordable, say so. A good plan uses the most effective options you can actually complete.

What this page cannot tell you

It cannot give current prices or confirm availability. Ask your hospital pharmacy and oncologist for up-to-date information.

Metastatic breast cancer is often treated for years with a sequence of drugs, so planning finances early helps avoid difficult interruptions.

Get estimates for the whole plan

Ask for the likely cost of the current treatment over several months, including tests and visits, not just the first dose.

Plan for tests and visits too

Newer drugs often need extra blood tests, scans or heart checks, which add to the overall cost.

Apply for support early

Support programmes can take weeks to approve. Start applications as soon as a new drug is recommended.

Keep documents organised

Support programmes and insurers ask for prescriptions, reports and bills. Keeping them together in one folder speeds up every application.

Review regularly

Prices and support options change. Ask your team to review costs at each change of treatment.

Honest conversations about money lead to better, more realistic treatment plans.

Raise cost early

Mention budget limits when treatment options are first discussed, not after a drug has been started.

Ask about equivalents

Ask whether an equally effective, more affordable option exists for your situation.

Ask what matters most

If money is limited, ask your oncologist which parts of the plan give the greatest benefit for your cancer. That helps prioritise spending on the treatments most likely to make a difference, rather than stretching funds thinly across everything.

Get help with applications

Hospital financial counsellors often help with support programme and scheme paperwork.